The joint effort will focus on providing patients with medication guidance, reminders, tracking of efficacy and health education.

You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy. This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply.

As the global obesity medication market skyrockets, South Korean pharmaceuticals are rushing to develop national obesity ...

Novo Nordisk's recent financial results and clinical progress haven't impressed Wall Street. Investors looking to strike ...

Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company's senior executives for ...

Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of ...

Novo Nordisk sees solid Q1 results, major GLP-1 growth potential, and limited downside despite guidance cut and rising risks.